HOUSTON, October 7, 2026
FibroBiologics, Inc. (Nasdaq: FBLG), a clinical-stage biotechnology company developing treatments for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it has filed a U.S. patent application for a cell-based technology designed to produce GLP-1, GIP, GLP-2 and other therapeutic peptides inside the body. The proposed approach uses engineered living cells organized into three-dimensional structures called spheroids or organoids to continuously produce and release therapeutic peptides after administration. The company believes this platform could offer a different approach to peptide delivery compared with conventional medicines that require repeated injections or daily oral dosing.
FibroBiologics Develops Cell-Based Peptide Delivery Technology
The patent application describes an approach in which engineered cells act as biological peptide-producing systems inside the body. Rather than administering a manufactured peptide repeatedly, the proposed technology is designed to use living cells grouped into three-dimensional structures that release selected therapeutic peptides over time. The application covers GLP-1, GIP and GLP-2 class peptides, along with other potential therapeutic peptides and their analogues. According to FibroBiologics, the approach is intended to provide continuous peptide production following administration, potentially reducing the need for frequent dosing. The company is exploring the technology in the context of medicines used for metabolic disorders, including diabetes and weight management. Many existing peptide-based treatments require scheduled injections or daily oral administration, creating an ongoing treatment burden for some patients. FibroBiologics proposes that continuous peptide release from engineered cells could offer an alternative delivery strategy. However, the approach remains at the patent-application and development-concept stage, and its ability to deliver reliable therapeutic levels, improve patient convenience or produce clinical benefits has not yet been established in humans.
Platform Targets GLP-1, GIP and Multiple Therapeutic Areas
Beyond GLP-1-based applications, FibroBiologics’ patent application describes potential use in gastrointestinal diseases, autoimmune and inflammatory conditions, wound healing, tissue regeneration, hormone deficiencies, cancer and age-related disorders. The proposed platform is not limited to one therapeutic molecule or one type of disease. It is intended to support the production of a range of therapeutic peptides and polypeptides, potentially expanding its application across several areas of medicine. The application also describes approaches for producing multiple peptides simultaneously at adjustable ratios. Different engineered cell populations could produce separate peptides, or cells could be designed to secrete combinations of therapeutic molecules. This flexibility could allow researchers to investigate different peptide combinations and production levels according to the intended indication. The technology may therefore have potential beyond single-agent GLP-1 delivery, although these proposed applications will require further development and validation. FibroBiologics also describes potential design features intended to address control and safety. These include immune-evasive modifications, inducible safety switches, integration of therapeutic genes at genomic safe-harbor sites, and encapsulation within biocompatible scaffolds or retrievable devices. Such features are proposed to support control over engineered-cell activity, duration and removal. Their performance and safety will need to be demonstrated through appropriate preclinical and clinical studies.
Advertisement
FibroBiologics Expands Its Cell Therapy Technology Pipeline
Founder and Chief Executive Officer Pete O’Heeron said the technology is intended to use engineered cells to manufacture and deliver therapeutic peptides continuously inside the body rather than relying exclusively on repeated administration of externally manufactured medicines. Chief Scientific Officer Hamid Khoja, Ph.D., highlighted the potential for living cells to produce and release peptides continuously and for distinct engineered cell populations to provide adjustable combinations. FibroBiologics is a clinical-stage biotechnology company based in Houston, Texas, focused on developing therapies and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials. The company reports that it has more than 270 issued and pending patents covering areas including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, cancer and human longevity. The newly announced patent application represents a proposed expansion of its technology platform into engineered-cell-based therapeutic peptide delivery. Filing a patent application does not itself establish that the technology will receive patent protection, enter clinical testing or become an approved treatment. Further research will be needed to determine its feasibility, safety and therapeutic potential.
Source: FibroBiologics press release
